DDInter381 DDInter785
Cinacalcet is a calcimimetic sold by Amgen under the trade name Sensipar® in North America and Australia and as Mimpara® in Europe. It is used to treat hyperparathyroidism due to parathyroid tumours or renal failure.
Fostamatinib has been investigated for the treatment and basic science of Rheumatoid Arthritis and Immune Thrombocytopenic Purpura (ITP). It was approved on April 17, 2018, under the trade name Tavalisse for use in ITP [L2644, FDA Label]. Fostamatinib has also been granted orphan drug status by the FDA . Recently, fostamatinib has been identified as a potential therapeutic for controlling acute respiratory distress syndrome (ARDS) in patients with severe COVID-19 through its ability to modulate the SYK kinase.[A235008, A235013, A235018]
Cinacalcet {u} (Compound) resembles {v} (Compound) Propranolol
Propranolol {u} (Compound) resembles {v} (Compound) Terbinafine
Terbinafine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fostamatinib
Cinacalcet {u} (Compound) resembles {v} (Compound) Duloxetine
Duloxetine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Esomeprazole
Esomeprazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fostamatinib
Cinacalcet {u} (Compound) resembles {v} (Compound) Duloxetine
Duloxetine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Epirubicin
Epirubicin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fostamatinib
Cinacalcet {u} (Compound) resembles {v} (Compound) Naftifine
Naftifine {u} (Compound) resembles {v} (Compound) Toremifene
Toremifene {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fostamatinib
Cinacalcet {u} (Compound) resembles {v} (Compound) Fluoxetine
Fluoxetine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Gilteritinib
Gilteritinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fostamatinib
Cinacalcet {u} (Compound) resembles {v} (Compound) Duloxetine
Duloxetine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Olaparib
Olaparib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fostamatinib
Cinacalcet {u} (Compound) resembles {v} (Compound) Dexfenfluramine
Dexfenfluramine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Tolterodine
Tolterodine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fostamatinib
Cinacalcet {u} (Compound) resembles {v} (Compound) Dexfenfluramine
Dexfenfluramine {u} may lead to a major life threatening interaction when taken with {v} Almotriptan
Almotriptan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fostamatinib
Cinacalcet {u} (Compound) resembles {v} (Compound) Duloxetine
Duloxetine {u} may lead to a major life threatening interaction when taken with {v} Sibutramine
Sibutramine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fostamatinib
Cinacalcet {u} (Compound) binds {v} (Gene) CYP1A2
CYP1A2 {u} (Gene) is bound by {v} (Compound) Daunorubicin
Daunorubicin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fostamatinib
Cinacalcet (Compound) resembles Propranolol (Compound) and Propranolol (Compound) resembles Terbinafine (Compound) and Terbinafine may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Cinacalcet (Compound) resembles Duloxetine (Compound) and Duloxetine may cause a minor interaction that can limit clinical effects when taken with Esomeprazole and Esomeprazole may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Cinacalcet (Compound) resembles Duloxetine (Compound) and Duloxetine may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Cinacalcet (Compound) resembles Naftifine (Compound) and Naftifine (Compound) resembles Toremifene (Compound) and Toremifene may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Cinacalcet (Compound) resembles Fluoxetine (Compound) and Fluoxetine may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib and Gilteritinib may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Cinacalcet (Compound) resembles Duloxetine (Compound) and Duloxetine may cause a moderate interaction that could exacerbate diseases when taken with Olaparib and Olaparib may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Cinacalcet (Compound) resembles Dexfenfluramine (Compound) and Dexfenfluramine may cause a minor interaction that can limit clinical effects when taken with Tolterodine and Tolterodine may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Cinacalcet (Compound) resembles Dexfenfluramine (Compound) and Dexfenfluramine may lead to a major life threatening interaction when taken with Almotriptan and Almotriptan may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Cinacalcet (Compound) resembles Duloxetine (Compound) and Duloxetine may lead to a major life threatening interaction when taken with Sibutramine and Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Cinacalcet (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Daunorubicin (Compound) and Daunorubicin may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib